FDA Approval and First Implant of Orsiro Mission Drug-Eluting Stent System in the U S prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
May 19, 2021
Compared with second-generation DES, devices with ultrathin struts are associated with less TLF, driven by reductions in clinically driven TLR, a long-term meta-analysis of multiple RCTs suggests.
The thinner struts have been thought to offer advantages in terms of producing less inflammation, vessel injury, neointimal proliferation, and thrombus formation. The new meta-analysis builds on the findings of a prior meta-analysis showing that ultrathin-strut DES were associated with a lower risk of TLF (composite of cardiac death, MI, or clinically driven TLR) at 1 year compared with conventional second-generation thin-strut DES.
Several additional
large-scale RCTs that have been completed in recent years, with extended follow-up to a mean of 2.5 years, differentiate the newer meta-analysis, which was presented today by Yousif Ahmad, MD (Cedars-Sinai Medical Center, Los Angeles, CA), at the EuroPCR 2021 virtual meeting. It was also simultaneously published in the
March 16, 2021
Between 1 and 2 years, the device-oriented advantage offered by an ultrathin-strut, biodegradable-polymer DES continues to accrue in patients treated for STEMI, the latest data from the BIOSTEMI trial show.
At 2 years, the rate of target lesion failure was 5.1% with the sirolimus-eluting Orsiro stent (Biotronik) and 8.1% with the thin-strut, durable-polymer, everolimus-eluting Xience Xpedition/Alpine (Abbott) stent, Thomas Pilgrim, MD (Bern University Hospital, Switzerland), reported this weekend during the virtual CRT 2021 meeting. At 1 year, the rates were 4% and 6% respectively.
“When we look at a landmark analysis with a time point at 1 year, we see actually that the difference still accrues over time,” senior investigator Juan F. Iglesias, MD (Geneva University Hospitals, Switzerland), told TCTMD. “The curves are still diverging,” which he said supports the idea that small differences in stent design can impact prognosis.
January 20, 2021
In Georgia, a teenage girl critically ill with COVID-19 complicated by fulminant myocarditis, heart failure, and multiorgan clots needed to get on extracorporeal membrane oxygen (ECMO) if she was to survive but doctors at the tertiary center didn’t have the staff to run the machines. They’d lost the majority of their permanent nurses to higher paid “travelling” positions elsewhere, so needed to request transfer.
In neighboring Florida, a cardiac/neuro lab tech, feeling undervalued, overworked, and unmotivated, made the difficult decision to give up her full-time position to become a traveler, accepting short-term positions at COVID-19 hotspots around the US.